Terray Therapeutics
Terray Therapeutics raises $120M Series B at $600M valuation
Quick Facts
Terray Therapeutics: Series B Funding Round
Terray Therapeutics has successfully raised $120M in Series B funding, reaching a valuation of $600M.
Company Overview
AI platform for small molecule drug discovery and development
Funding Details
The Series B round was led by Bedford Ridge Capital, with participation from NVentures.
Company Information
- Headquarters: Los Angeles, CA
- Founded: 2018
- Employees: 150+
- Category: Biotech
Investment
Terray Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Bedford Ridge Capital: Verified investor in Series B
- NVentures: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
